Biallelic Loss in DDR Genes and Its Clinical Impact

/in /by

Research presented during ASCO GU 2026, showed that germline DDR variants are common enough in metastatic prostate cancer to matter clinically, but their impact is highly gene-specific. In this 3,005-patient cohort, about 9% carried a germline DDR variant, and the study was especially important because it assessed both small variants and structural variants across 31 […]

Read more

How DNA “Switches” in Prostate Cancer May Open New Treatment Paths

/in /by

Researchers at USC have found that prostate cancer cells may rely on a 3D network of DNA “switches”, called enhancers, to keep cancer genes turned on. Enhancers are not genes themselves; they are stretches of DNA that help control when nearby or distant genes are active and how strongly they are expressed. In this study, […]

Read more

UPDATE: VIR-5500 Extended into mHSPC

/in , , /by

VIR-5500 expanded into mHSPC in April 2026, when it announced the first patient had been dosed in the Phase 1 dose-expansion cohorts. VIR-5500 is being studied in late-line mCRPC as monotherapy and, importantly for this expansion, in combination with an androgen receptor pathway inhibitor in early-line mCRPC and mHSPC. The move was built on earlier […]

Read more

UPDATE: SL-28 Phase 1/2 Trial Started To Recruit in Advanced Solid Tumors

/in , , , /by

A very interesting Phase 1/2 trial of SL‑28 has started enrolling up to 60 patients with advanced solid tumours at The Southern Oncology Clinical Research Unit (SOCRU). Although the study is open to a broad range of solid cancers, it is particularly noteworthy for prostate cancer because a published case report described a complete response […]

Read more

EvoPAR‑Prostate05 Phase 3 Trial: Saruparib Maintenance for Metastatic Hormone‑Sensitive Prostate Cancer

/in , , /by

EvoPAR‑Prostate05 is a Phase 3 maintenance trial testing the PARP1‑selective inhibitor saruparib (AZD5305) in men with metastatic hormone‑sensitive prostate cancer (mHSPC). The trial enrolls both HRR‑mutated and non‑HRR‑mutated patients but requires that each participant has confirmed homologous recombination repair mutation status (HRRm – genes such as BRCA1, BRCA2, ATM, PALB2, CDK12, RAD51B/C/D, or BARD1), homologous […]

Read more

Phase 2 Trial: Adaptive PSMA-PET–Guided 177Lu-DOTA-HYNIC-panPSMA (TLX597-Tx) in mHSPC

/in , , /by

The OPTIMAL-e trial is a phase 2 pilot study testing adaptive, PSMA-PET–guided radioligand therapy (RLT) with 177Lu-DOTA-HYNIC-panPSMA (TLX597-Tx) in men with metastatic hormone-sensitive prostate cancer (mHSPC), on top of standard androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI). Conducted at St Vincent’s Hospital in Sydney, it is single-arm, open-label, and nonrandomized, designed […]

Read more

CRISPR RNA Editing Turns “Invisible” Prostate Tumors into Targets for Immunotherapy

/in , , /by

Prostate cancer usually responds poorly to immunotherapy because the tumor hides from the immune system, earning the label of an “immune‑cold” cancer. A new RNA‑targeted CRISPR technology developed at Duke University School of Medicine and collaborating institutions re‑exposes these tumors to immune attack in mice by restoring a key protein complex on cancer cells that […]

Read more

Phase 1 Trial of SHY-ONC6, a Proteasome-Modulating Therapy in Solid Tumors (Including mCRPC)

/in , , /by

SHY-ONC6 is now entering a Phase 1 first-in-human clinical study in patients with advanced or metastatic solid tumors. The trial is open-label and multicenter, and its main goals are to assess safety, tolerability, pharmacokinetics, and early signs of anti-tumor activity in people whose disease has progressed on standard therapy or who cannot tolerate it. SHY-ONC6 […]

Read more